PuSH - Publication Server of Helmholtz Zentrum München

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

J. Am. Acad. Dermatol. 78, 872-881.e6 (2018)
Publishers Version DOI
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
as soon as is submitted to ZB.
Purpose of Review Advances in technology have expanded telemedicine opportunities covering medical practice, research, and education. This is of particular importance in movement disorders (MDs), where the combination of disease progression, mobility limitations, and the sparse distribution of MD specialists increase the difficulty to access. In this review, we discuss the prospects, challenges, and strategies for telemedicine in MDs.Recent Findings Telemedicine for MDs has been mainly evaluated in Parkinson's disease (PD) and compared to in-office care is cost-effective with similar clinical care, despite the barriers to engagement. However, particular groups including pediatric patients, rare MDs, and the use of telemedicine in underserved areas need further research.Summary Interdisciplinary telemedicine and tele-education for MDs are feasible, provide similar care, and reduce travel costs and travel time compared to in-person visits. These benefits have been mainly demonstrated for PD but serve as a model for further validation in other movement disorders.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Atopic Dermatitis ; Fezakinumab ; Il-22 ; Placebo-controlled Trial ; Moderate-to-severe Ad; Randomized Controlled-trial; Chronic Tic Disorders; Parkinsons-disease; Health-care; Tourette-syndrome; Behavior-therapy; Neurological Disorders; Huntington Disease; Batten-disease; Virtual Visits
Reviewing status
Institute(s) Institute of Environmental Medicine (IEM)